drugset
drugset / Trial / NCT01013818

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT01013818 ↗

Phase 1 Terminated 11 enrolled Human Genome Sciences Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.

Timeline

Start
2009-10
Primary completion
2011-10
Completion
2011-10

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to slow accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject HGS1029 Unknown — Intravenous

Indications

lymphoid neoplasm